유럽 장기 이식 진단 시장 : 분석 및 예측(2023-2033년)

“The Europe Organ Transplant Diagnostics Market Expected to Reach $3.35 Billion by 2033.”

Introduction to Europe Organ Transplant Diagnostics Market

In 2023, the Europe organ transplant diagnostics market was valued at $1.16 billion and is expected to reach $3.35 billion by 2033, with a CAGR of 11.15% during the forecast period 2023-2033. Several key factors are propelling growth in this sector, including a surge in the prevalence of chronic diseases resulting in organ failure, a heightened utilization of transplant diagnostics, a growing acceptance of stem cell therapy, an increase in leukemia cases driving demand for transplant diagnostic tests, the benefits derived from the advancement of molecular and genomic technologies in the field of transplant diagnostics, and the existence of favorable regulatory conditions, encompassing reimbursement schemes.

Market Introduction

The Europe organ transplant diagnostics market is experiencing significant growth driven by factors such as the increasing incidence of chronic diseases leading to organ failure. This rise in conditions like kidney, liver, and heart diseases fuels the demand for organ transplants and subsequently, transplant diagnostics. Adoption of transplant diagnostics is on the upswing due to advancements in medical technology and heightened awareness of the importance of pre-transplant compatibility testing. The growing acceptance of stem cell therapy also contributes to the demand for transplant diagnostics. Additionally, the prevalence of leukemia cases necessitates accurate diagnostic tests before bone marrow or stem cell transplantation. Advanced molecular and genomic technologies in transplant diagnostics enhance compatibility assessments. Europe's favorable regulatory environment, including reimbursement schemes, encourages investment in transplant diagnostics by healthcare providers and patients alike. These factors collectively drive growth in the Europe organ transplant diagnostics market, making it a dynamic sector for healthcare advancements.

Market Segmentation:

Segmentation 1: by Country

• Germany
• U.K.
• France
• Italy
• Spain
• Switzerland
• Rest-of-Europe

How can this report add value to an organization?

Growth/Marketing Strategy: The Europe organ transplant diagnostics market has witnessed major development by key players operating in the market, such as product launches, business expansions, partnerships, collaborations, mergers and acquisitions, funding activities, and regulatory and legal approvals. The favored strategy for the companies has been synergistic activities such as partnerships, collaborations, expansions, and funding activities.

Competitive Strategy: The key players in the Europe organ transplant diagnostics market analyzed and profiled in the study involve established and emerging players that offer different products and services for organ transplant diagnostics. Moreover, a detailed competitive benchmarking of the players operating in the Europe organ transplant diagnostics market has been done to help the reader understand the ways in which players stack against each other, presenting a clear market landscape. Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, and mergers and acquisitions will help the reader understand the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names in this market are:

Table of Contents

Executive Summary

1. Product Definition

• 1.1. Inclusion and Exclusion Criteria

2. Market Scope

• 2.1. Key Questions Answered in the Report:

3. Research Methodology

• 3.1. Organ Transplant Diagnostics Market: Research Methodology
• 3.2. Data Sources
  • 3.2.1. Primary Data Sources
  • 3.2.2. Secondary Data Sources
• 3.3. Market Estimation Model
• 3.4. Criteria for Company Profiling

4. Overview

• 4.1. Current Market Scenario
  • 4.1.1. For Researchers
  • 4.1.2. For Diagnostics
• 4.2. Market Footprint
• 4.3. COVID-19 Impact on Market
  • 4.3.1. Impact on Operations
  • 4.3.2. COVID-19 Impact: Current Scenario of Market
  • 4.3.3. Pre- and Post-COVID-19 Impact Assessment
    • 4.3.3.1. Pre-COVID-19 Phase
    • 4.3.3.2. Post-COVID-19 Phase

5. Europe

• 5.1. Europe
  • 5.1.1. Europe Organ Transplant Test Volume, by Transplant Type
  • 5.1.2. Market Sizing and Forecast
    • 5.1.2.1. Europe Organ Transplant Diagnostics Market (by Country)
      • 5.1.2.1.1. France
      • 5.1.2.1.2. Spain
      • 5.1.2.1.3. U.K.
      • 5.1.2.1.4. Italy
      • 5.1.2.1.5. Germany
      • 5.1.2.1.6. Switzerland
      • 5.1.2.1.7. Rest-of-Europe

6. Company Profiles

• 6.1. Overview
• 6.2. Manufacturers
  • 6.2.1. BAG Group GmbH
    • 6.2.1.1. Company Overview
    • 6.2.1.2. Role of BAG Group GmbH in the Organ Transplant Diagnostics Market
    • 6.2.1.3. Product Portfolio
    • 6.2.1.4. Analyst Perception
  • 6.2.2. bioMerieux S.A.
    • 6.2.2.1. Company Overview
    • 6.2.2.2. Role of bioMerieux S.A. in the Organ Transplant Diagnostics Market
    • 6.2.2.3. Product Portfolio
    • 6.2.2.4. Financials
    • 6.2.2.5. Recent Developments
    • 6.2.2.6. Analyst Perception
  • 6.2.3. Eurobio Scientific (Genome Diagnostics B.V.)
    • 6.2.3.1. Company Overview
    • 6.2.3.2. Role of Eurobio Scientific (Genome Diagnostics B.V.) in the Organ Transplant Diagnostics Market
    • 6.2.3.3. Product Portfolio
    • 6.2.3.4. Analyst Perception
  • 6.2.4. F. Hoffmann-La Roche Ltd.
    • 6.2.4.1. Company Overview
    • 6.2.4.2. Role of F. Hoffmann-La Roche Ltd. in the Organ Transplant Diagnostics Market
    • 6.2.4.3. Product Portfolio
    • 6.2.4.4. Financials
    • 6.2.4.5. Recent Developments
    • 6.2.4.6. Analyst Perception
  • 6.2.5. Omixon Inc.
    • 6.2.5.1. Company Overview
    • 6.2.5.2. Role of Omixon Inc. in the Organ Transplant Diagnostics Market
    • 6.2.5.3. Product Portfolio
    • 6.2.5.4. Analyst Perception
  • 6.2.6. QIAGEN N.V.
    • 6.2.6.1. Company Overview
    • 6.2.6.2. Role of QIAGEN N.V. in the Organ Transplant Diagnostics Market
    • 6.2.6.3. Product Portfolio
    • 6.2.6.4. Financials
    • 6.2.6.5. Recent Developments
    • 6.2.6.6. Analyst Perception